Literature DB >> 22965672

Tocilizumab for giant cell arteritis: an amazing result.

Metin Işık1, Levent Kılıç, İsmail Doğan, Meral Calgüneri.   

Abstract

Giant cell arteritis (GCA), previously Horton's disease, is a systemic vasculitis affecting the middle-sized or large arteries in patients older than 50 years of age. The mainstay of the treatment of GCA is glucocorticoid therapy. Herein, we present a case with giant cell arteritis resistant to oral and intravenous steroid, intravenous cyclophosphamide and mycophenolate mofetil, but successfully treated with tocilizumab.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22965672     DOI： 10.1007/s00296-012-2516-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  9 in total

1.  Tocilizumab: a novel therapy for patients with large-vessel vasculitis.

Authors:  Carlo Salvarani; Luca Magnani; Mariagrazia Catanoso; Nicolò Pipitone; Annibale Versari; Lucia Dardani; Lia Pulsatelli; Riccardo Meliconi; Luigi Boiardi
Journal:  Rheumatology (Oxford)       Date:  2011-11-10       Impact factor: 7.580

Review 2.  New therapies in the management of rheumatoid arthritis.

Authors:  Maya H Buch; Paul Emery
Journal:  Curr Opin Rheumatol       Date:  2011-05       Impact factor: 5.006

3.  Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis.

Authors:  Christian Beyer; Roland Axmann; Enijad Sahinbegovic; Jörg H Distler; Bernhard Manger; Georg Schett; Jochen Zwerina
Journal:  Ann Rheum Dis       Date:  2011-04-24       Impact factor: 19.103

Review 4.  Biologic treatment of large-vessel vasculitides.

Authors:  Valentin S Schäfer; Jochen Zwerina
Journal:  Curr Opin Rheumatol       Date:  2012-01       Impact factor: 5.006

5.  Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series.

Authors:  Michael Seitz; Stephan Reichenbach; Harald M Bonel; Sabine Adler; Felix Wermelinger; Peter M Villiger
Journal:  Swiss Med Wkly       Date:  2011-01-17       Impact factor: 2.193

6.  Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.

Authors:  M A González-Gay; R Blanco; V Rodríguez-Valverde; V M Martínez-Taboada; M Delgado-Rodriguez; M Figueroa; E Uriarte
Journal:  Arthritis Rheum       Date:  1998-08

7.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Authors:  Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2007-08

Review 8.  Giant cell arteritis: an updated review.

Authors:  Aki Kawasaki; Valerie Purvin
Journal:  Acta Ophthalmol       Date:  2008-10-07       Impact factor: 3.761

Review 9.  Polymyalgia rheumatica and giant-cell arteritis.

Authors:  Carlo Salvarani; Fabrizio Cantini; Gene G Hunder
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321
  9 in total
  4 in total

Review 1.  Biologic Therapy for the Treatment of Giant Cell Arteritis.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Rodney Tehrani; Walter Jay
Journal:  Neuroophthalmology       Date:  2014-04-02

Review 2.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

Review 3.  Tocilizumab: a new therapy for large vessel vasculitis.

Authors:  Ibrahim A Al-Homood
Journal:  Clin Exp Med       Date:  2013-08-15       Impact factor: 3.984

4.  Design of the tocilizumab in giant cell arteritis trial.

Authors:  Sebastian H Unizony; Bhaskar Dasgupta; Elena Fisheleva; Lucy Rowell; Georg Schett; Robert Spiera; Jochen Zwerina; Olivier Harari; John H Stone
Journal:  Int J Rheumatol       Date:  2013-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.